| 23rd week of 2014 patent applcation highlights part 41 |
| Patent application number | Title | Published |
|---|
| 20140154155 | REFINING METHODS AND AGENTS FOR RARE EARTH PRODUCTION - Hydrometallurgical systems, methods, and compositions are described in which organic amine-based lixiviants are utilized in the selective recovery of rare earth elements. The lixiviant can be regenerated in situ, permitting the organic amine to be used in substoichiometric amounts. | 2014-06-05 |
| 20140154156 | RECOVERY OF REUSABLE OSMIUM TETROXIDE - The present invention enables simple production of osmium tetroxide having comparable performance to that sold in reagents from a solution containing osmium. The present invention relates to a method for producing osmium tetroxide solution, the method comprising a step for using ozone or a similar oxidizing gas to oxidize a solution containing osmium and produce osmium tetroxide gas and a step for introducing the resulting osmium tetroxide gas into a recovery solution; the present invention further relates to a production apparatus therefor. | 2014-06-05 |
| 20140154157 | Process of Treating End-of-Life Cathode Ray Tubes for Lead and Soluble Silicates Recovery - There is described a process of recycling screen glass resulting from the disposal of cathode tube televisions, with quantitative recovery of lead in the form of sulphide and of silicates of cations other than lead, and subsequently recycling all the materials so recovered. | 2014-06-05 |
| 20140154158 | APPARATUS AND METHOD FOR REMOVING SULFER DIOXIDE FROM FLUE GASES - An apparatus and method for removing sulfur dioxide from a flue gas is described. The apparatus has sequentially operable scrubbing zone and regeneration zone, which communicate with one another via a molten eutectic mixture of lithium, sodium and potassium carbonates. In the scrubbing zone, an ingress flue gas interacts with the molten carbonates, resulting in chemical absorbance of the sulfur dioxide and in discharge of reaction gases. In the regeneration zone, ether a chemical or electrochemical melt regeneration takes place resulting in formation of sulfur-containing vapor which is cooled down for converting the sulfur-containing vapor into a liquid and solid phase for a further collection and utilization. | 2014-06-05 |
| 20140154159 | Engine Exhaust Aftertreatment Component Including Aftertreatment Brick Module - An engine exhaust aftertreatment component includes a housing defining an exhaust flow path from an exhaust inlet to an exhaust outlet. The housing supports an internal support channel. An aftertreatment brick module includes a catalytic brick, a can configured to receive the catalytic brick, and an end plate disposed along an end of the can. The end plate includes a coupling mechanism configured to be received within the internal support channel. | 2014-06-05 |
| 20140154160 | BIMETALLIC CATALYST - An emission control catalyst composition comprising a supported bimetallic catalyst consisting of gold and a metal selected from the group consisting of platinum, rhodium, ruthenium, copper and nickel is disclosed. Also disclosed is a catalytic convertor comprising a substrate monolith coated with the emission control catalyst composition and a lean burn internal combustion engine exhaust gas emission treatment system comprising the catalytic convertor. A variety of processes for preparing the catalyst composition are claimed. | 2014-06-05 |
| 20140154161 | METHOD AND APPARATUS FOR HYDROGEN SULPHIDE REMOVAL - A compact treatment apparatus and methodology is provided for scavenging at least H | 2014-06-05 |
| 20140154162 | SEPARATION OF CARBON DIOXIDE (CO2) FROM GAS MIXTURES BY CALCIUM BASED REACTION SEPARATION (CaRS-CO2) PROCESS - A reaction-based process developed for the selective removal of CO2 from a multicomponent gas mixture to provide a gaseous stream depleted in CO2 compared to the inlet CO2 concentration. The proposed process effects the separation of CO2 from a mixture of gases by its reaction with metal oxides. The Calcium based Reaction Separation for CO2 (CaRS—CO2) process consists of contacting CO2 laden gas with CaO in a reactor such that CaO captures CO2 by the formation of CaCO3. CaCO3 is regenerated by calcination leading to the formation of fresh CaO sorbent and the evolution of a concentrated stream of CO2. The “regenerated” CaO is then recycled for the further capture of CO2. This carbonation-calcination cycle forms the basis of the CaRS—CO2 process. This process also may use a mesoporous CaCO3 structure that attains >90% conversion over multiple carbonation and calcination cycles. | 2014-06-05 |
| 20140154163 | AMMONIA OXIDATION CATALYST - Provided is a catalyst article for treating an emission gas comprising (a) a noble metal catalyst layer comprising one or more noble metals disposed on a first refractory metal oxide support; and (b) a vanadium catalyst layer comprising vanadium pre-fixed on a second refractory metal oxide support selected from alumina, titania, zirconia, ceria, silica, and mixtures of these, wherein the first catalyst layer is in physical contact with said second catalyst layer. Also provided is a method for making such a catalyst article, a method for treating gas emissions using such an article, and an emission gas treatment system incorporating such an article. | 2014-06-05 |
| 20140154164 | NITRATE SALT-BASED PROCESS FOR MANUFACTURE OF GRAPHITE OXIDE - The present invention relates to a nitrate salt-based process for preparing a graphite oxide. The invention nitrate salt-based process employs starting materials comprising a sulfuric acid, an inorganic nitrate salt, an amount of water, a first amount of chlorate salt, and a graphite. | 2014-06-05 |
| 20140154165 | METHOD FOR PREPARING GRAPHENE BY USING TWO-DIMENSIONAL CONFINED SPACE BETWEEN THE LAYERS OF INORGANIC LAYERED MATERIALS - The present invention relates to a method for preparing graphene using the two-dimensional confined space between the layers of inorganic layered materials. Such method comprises the following steps: mix a soluble salt of a divalent metal ion M | 2014-06-05 |
| 20140154166 | EXFOLIATION OF GRAPHENE BY MULTILAYER COEXTRUSION - Exfolilation of graphene from graphite using multilayer coextrusion is generally disclosed. In some example embodiments, graphite may be dispersed within a first processing material, and the first processing material and a second processing material may be co-extruded through a plurality of series coupled layer multiplication dies to exfoliate graphene from the graphite. The graphene may be separated from the resulting multi-layered material. In some example embodiments, graphite flake and/or expanded graphite may be dispersed within the first processing material. | 2014-06-05 |
| 20140154167 | PROCESS FOR PREPARING TITANIUM TETRACHLORIDE USING OFF GASES FROM A SILICA AND ZIRCON CARBO-CHLORINATION PROCESS - This disclosure relates to an improved process for preparing titanium tetrachloride comprising a first carbo-chlorination reaction comprising reacting ores comprising silica and/or zirconium with chlorine and a carbon compound at a temperature of about 900° C. to about 1300° C. to form an unscrubbed off gas comprising carbon monoxide, and using the unscrubbed off gas in a second carbo-chlorination reaction comprising titanium to form titanium tetrachloride. | 2014-06-05 |
| 20140154168 | Process to obtain hydrogen peroxide, and catalyst supports for the same process - A catalyst support comprising a material functionalized with at least one acid group and at least one halogen atom; and a supported catalyst comprising (i) a catalyst and (ii) the catalyst support comprising the functionalized material, as well as their uses in production of hydrogen peroxide. A process for producing hydrogen peroxide, comprising reacting hydrogen and oxygen in the presence of the supported catalyst comprising the functionalized material, optionally with the addition of an inert gas, in a reactor. | 2014-06-05 |
| 20140154169 | SYSTEMS AND METHODS FOR PRODUCING HYDROGEN GAS - Systems and methods for thermally decomposing hydrocarbon feedstock may comprise a hydrocarbon feedstock, a non-oxidizing carrier gas, one or more heat exchangers, and a reaction chamber. The carrier gas may be used to transfer heat to the hydrocarbon feedstock. The heat exchanger(s) may be configured to heat the carrier gas. And the reaction chamber may be configured to receive hydrocarbon feedstock and heated carrier gas. Inside the reaction chamber, the hydrocarbon feedstock and the heated carrier gas may mix with one another causing the thermal decomposition reaction. The thermal decomposition reaction occurs in a substantially oxidant-free environment thereby eliminating or greatly reducing the production of carbon oxide byproducts. Hydrogen gas may be separated from a gaseous product stream that is thereafter collected from the reaction chamber. A portion of the gaseous product stream may be thermally coupled to the carrier gas and may thereafter be recycled through the system. | 2014-06-05 |
| 20140154170 | SYSTEMS AND METHODS FOR PRODUCING HYDROGEN GAS - Systems and methods for thermally decomposing hydrocarbon feedstock may comprise a hydrocarbon feedstock, a non-oxidizing carrier gas, one or more heat exchangers, and a reaction chamber. The carrier gas may be used to transfer heat to the hydrocarbon feedstock. The heat exchanger(s) may be configured to heat the carrier gas. And the reaction chamber may be configured to receive hydrocarbon feedstock and heated carrier gas. Inside the reaction chamber, the hydrocarbon feedstock and the heated carrier gas may mix with one another causing the thermal decomposition reaction. The thermal decomposition reaction occurs in a substantially oxidant-free environment thereby eliminating or greatly reducing the production of carbon oxide byproducts. Hydrogen gas may be separated from a gaseous product stream that is thereafter collected from the reaction chamber. A portion of the gaseous product stream may be thermally coupled to the carrier gas and may thereafter be recycled through the system. | 2014-06-05 |
| 20140154171 | Hydrogen Generation from Stabilized Alane - A hydrogen generator and a method of producing hydrogen gas using stabilized aluminum hydroxide and water are disclosed. The hydrogen generator contains stabilized aluminum hydride, water, a base, and a reaction chamber within which at least a portion of the stabilized aluminum hydride reacts with at least a portion of the water to produce hydrogen gas. The water that reacts with the stabilized aluminum hydride is contained in a basic aqueous solution including at least a portion of the base. The base can be included with the water in the basic aqueous solution, stored in a reservoir separate from the stabilized aluminum hydroxide, or the base can be a solid contained in a mixture with the stabilized aluminum hydroxide and mix with water when added to the mixture to form the basic aqueous solution. | 2014-06-05 |
| 20140154172 | TWO STEP NOVEL HYDROGEN SYSTEM USING ADDITIVES TO ENHANCE HYDROGEN RELEASE FROM THE HYDROLYSIS OF ALANE AND ACTIVATED ALUMINUM - A system for the generation of hydrogen for use in portable power systems is set forth utilizing a two-step process that involves the thermal decomposition of AlH | 2014-06-05 |
| 20140154173 | METHODS AND SYSTEMS FOR PRODUCING HYDROGEN - Exemplary embodiments of methods and systems for hydrogen production using an electro-activated material are provided. In some exemplary embodiments, carbon can be electro-activated and used in a chemical reaction with water and a fuel, such as aluminum, to generate hydrogen, where the by-products are electro-activated carbon, and aluminum oxide or aluminum hydroxide. Controlling the temperature of the reaction, and the amounts of aluminum and electro-activated carbon can provide hydrogen on demand at a desired rate of hydrogen generation. | 2014-06-05 |
| 20140154174 | PROCESS AND ZEOLITIC MATERIALS FOR THE SEPARATION OF GASES - The present invention relates to a process for the separation of gases which comprises putting a mixture of gases in contact with a zeolite of the ESV type to obtain the selective adsorption of at least one of the gases forming the gaseous mixture. The present invention also relates to particular zeolitic compositions suitable as adsorbents. | 2014-06-05 |
| 20140154175 | STABILIZED MICROPOROUS CRYSTALLINE MATERIAL, THE METHOD OF MAKING THE SAME, AND THE USE FOR SELECTIVE CATALYTIC REDUCTION OF NOX - There is disclosed a microporous crystalline material having pore opening ranging from 3 to 5 Angstroms, where the material comprises a first metal chosen from alkali earth group, rare earth group, alkali group, or mixtures thereof, and a second metal chosen from iron, copper or mixtures thereof; and has a molar silica to alumina ratio (SAR) from 3 to 10. The microporous crystalline material disclosed herein may comprise a crystal structure having building units of double-6-rings (d6r) and pore opening of 8-rings as exemplified with framework types defined by the Structure Commission of the International Zeolite Association having structural codes of CHA, LEV, AEI, AFT, AFX, EAB, ERI, KFI, SAT, TSC, and SAV. There is also disclosed a method of selective catalytic reduction of nitrogen oxides in exhaust gas, comprising at least partially contacting the exhaust gases with an article comprising the disclosed microporous crystalline material. | 2014-06-05 |
| 20140154176 | SILICOMETALLOPHOSPHATE MOLECULAR SIEVES, METHOD OF PREPARATION AND USE - A new family of crystalline microporous metallophosphates designated MAPSO-64 has been synthesized. These metallophosphates are represented by the empirical formula | 2014-06-05 |
| 20140154177 | METALLOPHOSPHATE MOLECULAR SIEVES, METHOD OF PREPARATION AND USE - A new family of crystalline microporous metallophosphates designated AlPO-67 has been synthesized. These metallophosphates are represented by the empirical formula | 2014-06-05 |
| 20140154178 | METHODS OF DETECTING MYELIN BASIC PROTEIN - A method and a kit for detecting myelin basic protein are provided. The method comprises administering an agent, which binds to myelin basic protein (MBP), to a subject at risk of or diagnosed with a myelin-associated neuropathy, and determining myelination by detecting the agent resided in the subject. The amount of the agent present in the subject is indicative of a myelin-associated neuropathy. A method of quantifying an amount of MBP present in a tissue sample is also provided, wherein the method comprises contacting the tissue sample with the same agent, detecting the agent present in the tissue sample; and quantifying an amount of the agent present in the tissue sample. | 2014-06-05 |
| 20140154179 | CXCR7 ANTAGONISTS - Compounds having formula I, | 2014-06-05 |
| 20140154180 | Pharmacophores for Amyloid Fibers Involved in Alzheimer's Disease - This invention relates, e.g., to a method for designing or selecting on a computer a candidate small molecule amyloid binder or inhibitor, comprising: a) docking test compounds to the binding site or binding surface determined from the three-dimensional structure of a co-crystal of a protofilament of an amyloid protein bound to a small molecule which is known to bind to the amyloid protein, and (b) selecting test compounds which exhibit an energy below that of the small molecule used to form the co-crystal made in a), as candidate amyloid binders. | 2014-06-05 |
| 20140154181 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF - The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radioimaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for targeted chemotherapy. | 2014-06-05 |
| 20140154182 | N,N-SUBSTITUTED GUANIDINE COMPOUND - The invention is directed to a N,N-substituted guanidine compound or a salt or solvate thereof according to formula (1), R | 2014-06-05 |
| 20140154183 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION - What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use. | 2014-06-05 |
| 20140154184 | TIME-GATED FLUORESCENCE IMAGING WITH SI-CONTAINING PARTICLES - A method for imaging leverages the fluorescence lifetime of a fluorescent Si-containing particle to distinguish from background fluorescence. A particle is introduced into tissue. An excitation light pulse is applied to excite luminescence from the fluorescent Si-containing particle. Time-gated measuring of a responsive luminescence signal identifies the particle. In preferred embodiments the particle is coated or encapsulated with an organic material. The fluorescence lifetime of particles can be controlled during manufacture, such as by oxidation levels, quenching treatments, or by aging. This permits introducing and using groups of particles in imaging that have unique lifetimes and multiple time gating can be used to identify different particles or to monitor the change in lifetime of a single set of particles as they respond to a biochemical stimulus. The particles can also be functionalized for affinity to particular tissues and can be loaded with treatment molecules. | 2014-06-05 |
| 20140154185 | USE OF NON-LABELED SUGARS AND DETECTION BY MRI FOR ASSESSING TISSUE PERFUSION AND METABOLISM - A method for magnetic resonance (MR) imaging or spectroscopy on a MR scanner to detect tissue physiological parameters in one or more tissue areas in a human or non-human subject includes administering to the subject a contrast enhancing physiologically tolerable amount of a sugar that is non-labeled, subjecting the subject to an MR procedure capable of generating MR signals encoding at least one tissue area in the subject in which the sugar either passes or is taken up, detecting a temporal variation in the MR signals in the at least one tissue area after the administering the sugar, determining at least one tissue-related parameter from the temporal variation, and ascertaining whether the at least one tissue-related parameter is abnormal. | 2014-06-05 |
| 20140154186 | BACTERIOCHLORIN IMIDES - Compound of Formula I: are described, along with compositions containing the same and methods of use thereof. | 2014-06-05 |
| 20140154187 | Liquid Tooth Paste - My tooth cream will not stick, this is what makes it different from other tooth pastes. It can be dispensed in any type container, but it is different in that this toothpaste contains NO thickeners, no carrageenan, no cellulose gum, no glycerin and no SLS (sodium lanyl sulfates). My tooth crème can contain colorings, flavorings, preservatives, xylitol, sweetnings, fluoride . . . infinity. | 2014-06-05 |
| 20140154188 | COMPOSITION CONTAINING A CELLULOSE, A VEGETABLE OIL AND A VOLATILE SOLVENT, AND USE THREOF AS A DRESSING - The present invention relates to a composition in the fluid form intended to form a dressing on the skin. This composition comprises from 6% to 12% by weight of the total weight of the composition of a cellulose derivative, from 5% to 15% by weight of the total weight of the composition of a vegetable oil, and a volatile solvent. The oil/cellulose ratio by weight is between 0.8 and 1.5. | 2014-06-05 |
| 20140154189 | Biocidal Compositions Comprising Iron Chelators - The present invention, therefore, is directed to an antimicrobial compositions that decreases the bioavailability of iron by introducing a higher-affinity iron-selective chelating agent capable of competing with microbial siderophores. In one aspect, the present invention relates to an antimicrobial composition including a potentiating antimicrobial composition including one or more antimicrobial agents and a chelator having a weight ratio of the antimicrobial agent to the chelator from about 1:1000 to about 1000:1. | 2014-06-05 |
| 20140154190 | Skin Lightening Compositions - Compositions and methods for lightening and/or depigmenting skin are provided, the compositions comprising compounds having the structure: | 2014-06-05 |
| 20140154191 | USE OF COSMETICS AGAINST INFRARED RADIATION - The disclosure relates to a cosmetic composition for use in protecting the human skin against infrared (IR) radiation. The cosmetic composition includes a first plant extract mixture of Green Coffee Seed Extract, | 2014-06-05 |
| 20140154192 | GLUTATHIONE ANALOGS AND USES THEREOF - The invention provides compounds of formula (I): (I) or salts thereof, wherein R1, R2, R3 Z, and X have any of the values defined herein, as well as compositions comprising such compounds. The compounds and compositions are useful for treating neurodegenerative disorders. | 2014-06-05 |
| 20140154193 | FORMULATION AND METHOD FOR THE TREATMENT OF FUNGAL NAIL INFECTIONS - The present invention relates to a formulation and method for the treatment of fungal nail infections, such as those caused by | 2014-06-05 |
| 20140154194 | Skin Whitening Composition Containing Chia Seed Extract - A topical composition includes an alcohol-extracted | 2014-06-05 |
| 20140154195 | Topical Compositions Containing White Strawberry Extract - Topical skin care composition comprising an extract of white strawberry and at least one additional skin care active. | 2014-06-05 |
| 20140154196 | COSMETIC COMPOSITION BASED ON A SUPRAMOLECULAR POLYMER AND A SILICONE COMPOUND - The present invention relates to a process for making up and/or caring for the skin and/or the lips, comprising the application to the skin and/or the lips of a cosmetic composition and in particular a composition for making up and/or caring for the skin and/or the lips, comprising at least one supramolecular polymer and a silicone compound with a viscosity of less than 10 000 000 cSt at 25° C. | 2014-06-05 |
| 20140154197 | Packaged Antiperspirant Compositions - A packaged antiperspirant product is provided. The packaged antiperspirant product includes an anhydrous antiperspirant composition having from 40% to 60%, by weight of the anhydrous antiperspirant composition, of solids. The solids include an antiperspirant active, one or more waxes, and one or more fillers having a total concentration from about 15% to about 35% by weight of the anhydrous antiperspirant composition. The antiperspirant composition also has from about 35% to about 60%, by weight of the composition, of one or more carriers other than water, wherein the one or more carriers comprises a non-volatile silicone fluid. The package includes a container body having an interior chamber storing the anhydrous antiperspirant composition, a dome closing one end of the container body and having a plurality of apertures extending through the thickness of the dome. An elevator and feed screw are disposed within the container body. | 2014-06-05 |
| 20140154198 | Compositions and Methods for Tinting Keratin Material - A cosmetic composition comprising at least one volatile solvent, at least one crosslinked silicone film former, at least one silicone gum, and at least one pigment composition present in an amount sufficient to provide the cosmetic composition with a pigment contrast ratio of greater than 35 and a method for maximizing the intensity and opacity of a color cosmetic composition. | 2014-06-05 |
| 20140154199 | SILICONE-CONTAINING COMPOSITION AND PERSONAL CARE PRODUCTS CONTAINING SAME - A silicone composition, especially advantageous for incorporation in a personal care product, includes a silicone resin (a) and a silicone gum (b), the mixture of resin (a) and gum (b) having a softening point of 50° C. or greater and an elastic modulus at ambient temperature of 10 | 2014-06-05 |
| 20140154200 | Guar hydroxypropyltrimethylammonium chloride and uses thereof in hair treatment compositions - The present invention relates to a non-cellulosic polysaccharide derivative:
| 2014-06-05 |
| 20140154201 | SELF-ADHESIVE FRAGRANCED GELS - A method for dispensing an active volatile in the environment surrounding a surface, which comprises applying to the surface a self-adhering, water-resistant gel composition of at least one active volatile ingredient, silica, and a water-soluble cationic polysaccharide, and diffusing or releasing the volatile ingredient(s) from the gel in an amount sufficient to purify or sanitize the surrounding air, both in a dry condition or in the presence of humidity or water. The gel composition remains adhered to the surface and actively releases the volatile ingredient(s) even after being exposed to repeated water flows over the composition. | 2014-06-05 |
| 20140154202 | PROCESS FOR THE IDENTIFICATION OF COMPOUNDS FOR TREATING CANCER - Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer. | 2014-06-05 |
| 20140154203 | Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using The Same - The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules. | 2014-06-05 |
| 20140154204 | SILANE-CONTAINING MOISTURE-CURABLE TISSUE SEALANT - A tissue sealant that includes the reaction product of (a) a polyol; (b) a polyisocyanate; and (c) an alkoxy silane having the formula: (R | 2014-06-05 |
| 20140154205 | ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR THERAPEUTIC AND COSMETIC APPLICATIONS - A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm | 2014-06-05 |
| 20140154206 | IMMUNITY INDUCTION AGENT - Provided is a novel immunity-inducing agent useful as a therapeutic and/or prophylactic agent for cancer. The immunity-inducing agent comprises as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a), (b) and (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, which recombinant vector(s) is/are capable of expressing the polypeptide(s) in vivo: (a) a polypeptide composed of not less than 7 consecutive amino acids in any one of the amino acid sequences of SEQ ID NOs:4, 2, 22 and 24 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 90% to the polypeptide (a) and composed of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof. | 2014-06-05 |
| 20140154207 | KIT CONTAINING STEM CELLS AND CYTOKINES FOR USE IN ATTENUATING IMMUNE RESPONSES - The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD). | 2014-06-05 |
| 20140154208 | Novel [N-Me-4-hydroxyleucine]-9-Cyclosporin Analogues for Treatment and Prevention of Hepatitis C Infection - The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 2014-06-05 |
| 20140154209 | POLYMORPHISMS ASSOCIATED WITH NON-RESPONSE TO A HEPATITIS C TREATMENT OR SUSCEPTIBILITY TO NON-SPONTANEOUS HEPATITIS C CLEARANCE - The present invention relates to in vitro methods of determining a susceptibility to non-response to a hepatitis C treatment or a susceptibility to non spontaneous hepatitis C clearance in a subject infected with hepatitis C. | 2014-06-05 |
| 20140154210 | Solid Forms of a Thiophosphoramidate Nucleotide Prodrug - The present application relates to solid state forms, for example, crystalline forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents. | 2014-06-05 |
| 20140154211 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to 2′-Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, R | 2014-06-05 |
| 20140154212 | CROSSLINKED GELATIN HYDROGELS - Hydrogels based on gelatin crosslinked with N,N′-methylenebisacrylamide (MBA) are disclosed. The hydrogels according to the invention are useful for cell culture, growth and proliferation, for the controlled release of bioactive molecules, and to promote tissue regeneration. | 2014-06-05 |
| 20140154213 | RECOMBINANT VECTOR FOR PRODUCING AND SECRETING PEPTIDE OR PROTEIN OF INTEREST BY PROPIONIBACTERIA AND APPLICATIONS THEREOF - The present invention relates to a recombinant vector for expressing and secreting, by a | 2014-06-05 |
| 20140154214 | SELECTIVE GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES - GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 11, 16, 20, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 and one or more of positions 3, 5, 7, and 10, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. | 2014-06-05 |
| 20140154215 | HERPES VIRUS STRAINS - The present invention provides a herpes virus with improved oncolytic properties which comprises a gene encoding an immunomodulatory cytokine and which lacks a functional ICP34.5 gene and a functional ICP47 encoding gene. | 2014-06-05 |
| 20140154216 | VIRUS STRAINS - The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains. | 2014-06-05 |
| 20140154217 | LACTOCOCCUS LACTIS STRAINS, AND BACTERIAL PREPARATIONS THEREOF, FOR THE PRODUCTION OF BIOACTIVE PEPTIDES HAVING ANTI-HYPERTENSIVE AND CHOLESTEROL-LOWERING EFFECTS IN MAMMALS; NUTRITIONAL AND THERAPEUTIC PRODUCTS PRODUCED THEREFROM | 2014-06-05 |
| 20140154218 | ANTI-ALLERGIC AGENT - According to the present invention, an anti-allergic agent is provided which includes a polysaccharide comprising galactose, glucose and rhamnose as constituents, or includes a microorganism belonging to a genus | 2014-06-05 |
| 20140154219 | METHODS AND COMPOSITIONS FOR LARGE-SCALE ISOLATION OF VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS - Methods for purifying very small embryonic-like (VSEL) stem cells from populations of cells suspected of including VSEL stem cells are provided. In some embodiments, the methods include (a) providing a population of cells suspected of including a VSEL stem cell; and (b) isolating a CD45 | 2014-06-05 |
| 20140154220 | Methods and Compositions for Improved Tissue Regeneration by Suppression of Interferon-Gamma and Tumor Necrosis Factor-Alpha - The present invention discloses methods, compositions and devices for improving tissue regeneration by suppressing the effects of several proinflammatory cytokines such as TNF-α and IFN-γ. Compositions and devices of this invention will generally include one or more anti-inflammatory agent(s) capable of reducing the level of TNF-α, IFN-γ, or both. Methods for improving tissue regeneration in accordance with this invention will generally have the step of applying a composition or device of the invention to a site in need of the composition or device. Also disclosed are methods for forming composition and devices of the invention and pharmaceutical compositions comprising one or more anti-inflammatory agent(s) effective of inhibiting or reducing the levels of TNF-α, IFN-γ, or both. | 2014-06-05 |
| 20140154221 | TREATMENT METHOD FOR MESENCHYMAL STEM CELLS AND THEIR APPLICATION AS A TREATMENT OF OXIDATIVE STRESS RELATED DISEASES - The present invention relates to a method of treatment of mesenchymal stem cells, preferably from adipose origin, comprising mainly two stages, firstly the collection and isolation of mesenchymal stem cells, and secondly, a period of growth and specific treatment of cells in a conditioning or treatment medium with an oxidizing agent. The invention also comprises the cells obtained directly through the method and its use in treating diseases caused by or associated with oxidative stress. | 2014-06-05 |
| 20140154222 | ISOLATED CELLS AND POPULATIONS COMPRISING SAME FOR THE TREATMENT OF CNS DISEASES - An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype. | 2014-06-05 |
| 20140154223 | METHODS OF PEST CONTROL - Certain embodiments of the present invention provide a method for controlling | 2014-06-05 |
| 20140154224 | Method of Pest Control - The present invention provides a method for controlling | 2014-06-05 |
| 20140154225 | METHOD FOR COMBINED CONDITIONING AND CHEMOSELECTION IN A SINGLE CYCLE - A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity. | 2014-06-05 |
| 20140154226 | REGENERATION AND REPAIR OF NEURAL TISSUE USING POSTPARTUM-DERIVED CELLS - Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of neural tissue using the postpartum-derived cells are also disclosed. | 2014-06-05 |
| 20140154227 | CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES - The present invention provides a population of mesenchymal cells that do not express the cell surface markers CD112 and/or CD155 for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues. | 2014-06-05 |
| 20140154228 | ANTIGEN-SPECIFIC CENTRAL-MEMORY T CELL PREPARATIONS HAVING HIGH CD4+ FRACTION - The invention relates to a method for generation of T cell preparations that are specific for at least one target antigen, comprising the steps of expanding lymphoid cells in vitro in the presence of a target antigen or peptide fragments thereof in an expansion step, isolating cells that secrete interferon gamma and culturing, the cells in the presence of interleukin 2 and interleukin 7 and either an inhibitor of the mTOR Complex 1, or in the presence of an inhibitor of IL-2/IL-2R interaction. The invention further relates to preparations obtained by the method of the invention. | 2014-06-05 |
| 20140154229 | PROTEOLYTIC EXTRACT FROM BROMELAIN FOR THE TREATMENT OF CONNECTIVE TISSUE DISORDERS - The present invention relates to a proteolytic extract obtained from bromelain for the treatment of connective tissue diseases. In particular, the present invention relates to a pharmaceutical composition that includes proteolytic extract obtained from bromelain for the treatment of diseases such as Dupuytren's disease and Peyronie's disease. | 2014-06-05 |
| 20140154230 | Glycopegylated Factor IX - Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 2014-06-05 |
| 20140154231 | PROCESS FOR SEPARATING PROTEINS FIBRINOGEN, FACTOR XIII AND BIOLOGICAL GLUE FROM A SOLUBILIZED PLASMA FRACTION AND FOR PREPARING LYOPHILISED CONCENTRATES OF SAID PROTEINS - Process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins. | 2014-06-05 |
| 20140154232 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing - The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgd1α) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual. | 2014-06-05 |
| 20140154233 | METHOD OF PURIFYING THERAPEUTIC PROTEINS - The present invention relates generally to a method of reducing the level of plasminogen and/or tissue plasminogen activator and/or other protease(s) in a solution comprising fibrinogen and/or Factor VIII and/or von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising fibrinogen and/or Factor VIII and/or VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that the plasminogen and/or tissue plasminogen activator and/or other protease(s) is bound to the resin; and (ii) recovering the solution comprising fibrinogen and/or Factor VIII and/or VWF which passes through the resin; wherein the concentration of the plasminogen and/or tissue plasminogen activator and/or protease(s) in the recovered solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof. | 2014-06-05 |
| 20140154234 | METHOD FOR GENERATING THROMBIN - Methods of generating thrombin and methods of applying a clotting tissue sealant to a site on a subject are provided. A blood component comprising platelets can be obtained from the subject. A hypotonic composition is contacted with a solid matrix to form a thrombin-containing liquid, where the hypotonic composition includes water, calcium, a blood component comprising platelets, and optionally a chelator. Calcium is present in the hypotonic composition in an amount greater than the amount of calcium that can be complexed by the chelator. Thrombin-containing liquid is then separated from the hypotonic composition and can be applied to the site on the subject to form a clot, for example, by combination with fibrinogen. | 2014-06-05 |
| 20140154235 | WOUND DEBRIDEMENT COMPOSITIONS CONTAINING SEAPROSE AND METHODS OF WOUND TREATMENT USING SAME - Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds. | 2014-06-05 |
| 20140154236 | DEVICES AND METHODS FOR TREATING PAIN ASSOCIATED WITH TONSILLECTOMIES - Described here are devices and methods for treating one or more conditions or symptoms associated with a tonsil procedure. In some variations, a drug-releasing device may be at least partially delivered to one or more tonsillar tissues before, during, or after a tonsil procedure. In some variations, the drug-releasing device may be configured to be biodegradable. In other variations, the drug-releasing device may comprise one or more hemostatic materials or one or more adhesives. The drug-releasing device may be configured to release one or more drugs or agents, such as, for example, one or more analgesics, local anesthetics, vasoconstrictors, antibiotics, combinations thereof and the like. | 2014-06-05 |
| 20140154237 | METHODS AND KITS FOR TOPICAL APPLICATION, REMOVAL, AND INACTIVATION OF THERAPEUTIC OR COSMETIC TOXIN COMPOSITIONS - This invention relates to methods and kits for safely removing and inactivating topical therapeutic or cosmetic compositions. The methods and kits according to the invention are particularly well suited for removing and inactivating highly toxic substances. | 2014-06-05 |
| 20140154238 | Compositions And Methods For Treating, Diagnosing And Monitoring Disease - Compositions and methods which inhibit the expression of the TMEM92 gene or which inhibits the function of die TMEM92 protein can be used for treating, diagnosing and monitoring disease, for example cancer. | 2014-06-05 |
| 20140154239 | Anti-interferon alpha monoclonal antibodies and methods for use - The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease. | 2014-06-05 |
| 20140154240 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT - The invention provides compounds of Formula I or Formula II: | 2014-06-05 |
| 20140154241 | BINDING PEPTIDES I - A modified igNAR peptide sequence derived from a wild-type igNAR peptide sequence is diversified by mutating the amino acid sequence at 50% or more of the amino acids in the CDR3 loop region and optionally at 50% or more of the amino acids in the CDR3 loop region. The modified igNAR peptide may have the sequence of SEQ ID NO: 8, 10 or 50 to 85. The modified igNAR peptides have binding activity against albumin protein sequences, such as human serum albumin. These modified igNAR peptides may have utility in extending the in vivo half-life of biological molecules e.g. therapeutic agents, and so may be used in medicine. | 2014-06-05 |
| 20140154242 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF - The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases. | 2014-06-05 |
| 20140154243 | SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR - Specific binding agents that interact with hepatocyte growth factor (HGF) are described. Methods of treating cancer by administering a pharmaceutically effective amount of a specific binding agent to HGF are described. Methods of detecting the amount of HGF in a sample using a specific binding agent to HGF are described. | 2014-06-05 |
| 20140154244 | Methods of Treating Primary Brain Tumors by Administering Letrozole - The present disclosure relates to the field of cancer treatment, and more specifically to the field of treatment of primary malignant brain tumors. Provided herein are methods of treating primary brain tumors, including gliomas, by administering to a patient in need thereof a therapeutically effective amount of the aromatase inhibitor letrozole. | 2014-06-05 |
| 20140154245 | HUMANIZED ANTI-EMAP II ANTIBODY AND USE THEREOF - The present invention provides a humanized anti-EMAP II antibody, the use of the humanized antibody, and pharmaceutical compositions containing the humanized antibody. The humanized anti-EMAP II antibody shows reduced immunogenicity and increased half-life while having similar or improved antigen binding capacity compared to the parent monoclonal antibody. Thus, the humanized anti-EMAP II antibody of the present invention can be more effectively used as a diagnostic reagent for EMAP II and a therapeutic agent for diseases that are mediated by EMAP II. | 2014-06-05 |
| 20140154246 | CAI-BASED SYSTEMS AND METHODS FOR THE LOCALIZED TREATMENT OF OCULAR AND OTHER DISEASES - The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies), that are effective and are associated with little or no adverse side effects. | 2014-06-05 |
| 20140154247 | Biological Markers and Methods for Predicting Response to B-Cell Antagonists - Biological markers that predict patient responsiveness to B-cell antagonists are provided. Also provided are methods of using such biological markers. In addition, methods for identifying patients suffering from an autoimmune disease, e.g., rheumatoid arthritis, who are not likely to respond to B-cell antagonists are provided, as are methods of treating such patients. Methods for selecting therapeutic agents to treat such patients are also provided. | 2014-06-05 |
| 20140154248 | RECOMBINANT IMMUNOTOXIN TARGETING MESOTHELIN - Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to improved recombinant immunotoxins comprising anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and a | 2014-06-05 |
| 20140154249 | NOVEL CHEMOKINE BINDING POLYPEPTIDES CAPABLE OF INHIBITING THE COURSE OF AUTOIMMUNITY, INFLAMMATION AND CANCER - Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions. | 2014-06-05 |
| 20140154250 | SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION - The present disclosure relates to single-chain multivalent binding proteins, compositions comprising the single-chain multivalent binding proteins, and methods of making and using the single chain-multivalent binding proteins. | 2014-06-05 |
| 20140154251 | ANTI C-MET ANTIBODY AND USES THEREOF - An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided. | 2014-06-05 |
| 20140154252 | SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION - Variations on the structural themes for multivalent binding molecules with effector function, or scorpions, will be apparent to those of skill in the art upon review of the present disclosure, and such variant structures are within the scope of the invention. | 2014-06-05 |
| 20140154253 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs - Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3. | 2014-06-05 |
| 20140154254 | HETERODIMERIC IMMUNOGLOBULINS - The present application is directed to heterodimeric antibodies and methods of use. | 2014-06-05 |
